BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21185573)

  • 21. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
    Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
    J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas.
    Stockhammer F; Thomale UW; Plotkin M; Hartmann C; Von Deimling A
    J Neurosurg; 2007 Apr; 106(4):633-7. PubMed ID: 17432715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
    Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
    Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
    Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
    Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.
    Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W
    Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.
    Ferrer-Luna R; Mata M; Núñez L; Calvar J; Dasí F; Arias E; Piquer J; Cerdá-Nicolás M; Taratuto AL; Sevlever G; Celda B; Martinetto H
    J Neurooncol; 2009 Dec; 95(3):343-354. PubMed ID: 19597701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reclassification of oligoastrocytomas by loss of heterozygosity studies.
    Eoli M; Bissola L; Bruzzone MG; Pollo B; Maccagnano C; De Simone T; Valletta L; Silvani A; Bianchessi D; Broggi G; Boiardi A; Finocchiaro G
    Int J Cancer; 2006 Jul; 119(1):84-90. PubMed ID: 16432842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of 14q chromosome in oligodendroglial and astrocytic tumors.
    Dichamp C; Taillibert S; Aguirre-Cruz L; Lejeune J; Marie Y; Kujas M; Delattre JY; Hoang-Xuan K; Sanson M
    J Neurooncol; 2004 May; 67(3):281-5. PubMed ID: 15164983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
    Jha P; Agarwal S; Pathak P; Srivastava A; Suri V; Sharma MC; Chosdol K; Srivastava T; Gupta D; Gupta A; Suri A; Sarkar C
    Cancer Genet Cytogenet; 2010 Apr; 198(2):126-34. PubMed ID: 20362227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seizures in patients with IDH-mutated lower grade gliomas.
    Carstam L; Rydén I; Jakola AS
    J Neurooncol; 2022 Nov; 160(2):403-411. PubMed ID: 36258151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
    Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
    [No Abstract]   [Full Text] [Related]  

  • 39. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.
    Godfraind C; Rousseau E; Ruchoux MM; Scaravilli F; Vikkula M
    Neuropathol Appl Neurobiol; 2003 Oct; 29(5):462-71. PubMed ID: 14507338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of genetic material within 1p and 19q chromosomal arms in low grade gliomas of central nervous system.
    Ręcławowicz D; Stempniewicz M; Biernat W; Limon J; Słoniewski P
    Folia Neuropathol; 2013; 51(1):26-32. PubMed ID: 23553134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.